News
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
OMS1620 is advancing through IND-enabling studies for diseases associated with ACTH excess, including congenital adrenal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback